10-Q: 10x Genomics Reports Q1 2025 Results, Revenue Mixed Amidst Litigation Settlement

10x Genomics' Q1 2025 revenue shows a mixed performance with a decrease in product sales offset by licensing revenue from a settlement with Vizgen.

Summary

• 10x Genomics reported a net loss of $34.4 million for Q1 2025, compared to a $59.9 million loss in Q1 2024.
• Revenue increased by 10% to $154.9 million, driven by a $17.1 million contribution from license and royalty revenue.
• Product and services revenue decreased by 2% to $137.8 million.
• Consumables revenue increased by 5% to $115.4 million, while instrument revenue decreased by 42% to $14.8 million.
• The company settled its patent litigation with Vizgen, receiving an upfront payment of $26.0 million, which was recorded as a $9.2 million gain on settlement and $16.8 million of license and royalty revenue.
• Cost of products and services revenue increased by 3% to $49.4 million.
• Research and development expenses decreased by 6% to $64.2 million.
• Selling, general and administrative expenses increased by 5% to $89.7 million.
• The company expects revenues, excluding the impact of license and royalty revenue, to be approximately flat in the second quarter of 2025.
• A reduction in force is expected to result in the termination of approximately 8% of the company's global workforce, with costs estimated between $5.5 million and $6.5 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue increased due to a one-time settlement, core product sales were down. Cost-cutting measures are being implemented, but the company is still operating at a loss.

Positives

• Total revenue increased by 10% year-over-year.
• Consumables revenue increased by 5% year-over-year.
• Services revenue increased significantly by 47%.
• Gross margin improved to 68% due to license and royalty revenue and lower manufacturing costs.
• Research and development expenses decreased by 6%.

Negatives

• Net loss remains significant at $34.4 million.
• Product and services revenue decreased by 2%.
• Instrument revenue decreased significantly by 42%.
• Selling, general and administrative expenses increased by 5%.

Risks

• Fluctuations in operating results due to various factors, including competition and changes in customer demand.
• Dependency on government funding and research and development spending by research institutions.
• Potential impact of trade tariffs, import restrictions, and export restrictions.
• Challenges in managing product transitions and forecasting customer demand.
• Risks associated with doing business internationally, including currency exchange rates and regulatory compliance.
• Potential for increased litigation and intellectual property disputes.
• Dependence on single-source suppliers for certain equipment, components, and materials.
• Risk of manufacturing defects or quality control issues.
• Uncertainties related to the size of the market for the company's solutions.
• Potential for undetected errors or defects in the company's solutions.
• The company expects to continue to incur operating losses for the foreseeable future.
• The company is implementing a reduction in force that may result in negative unintended consequences.

Future Outlook

The company expects revenues, excluding the impact of license and royalty revenue, to be approximately flat in the second quarter of 2025 and expects operating expenses to trend lower in 2025.

Management Comments

• The company is taking actions to reduce operating costs, including a reduction in force and planned reductions in non-headcount operating expenses.

Industry Context

The life sciences tools market is highly competitive, with companies constantly innovating and introducing new products. 10x Genomics faces competition from established players and emerging companies, as well as researchers developing their own solutions.

Comparison to Industry Standards

• It's difficult to directly compare 10x Genomics' Q1 2025 results to industry standards without specific competitor data for the same period.
• However, companies like Illumina, NanoString (now Bruker), and Bio-Rad are key competitors in the genomics and spatial biology space.
• Illumina, as the leader in sequencing technology, often sets the benchmark for revenue and growth in the genomics market.
• NanoString, before its acquisition by Bruker, was a direct competitor in spatial biology, and its performance provided a reference point for market trends.
• Bio-Rad competes in various areas, including single-cell analysis, and its financial results can indicate broader trends in the life science tools market.
• Given the decrease in 10x Genomics' instrument revenue, it's important to compare this against instrument sales trends reported by competitors to assess if this is company-specific or an industry-wide trend.
• The increase in consumables revenue aligns with the general expectation that installed instruments drive recurring revenue from consumables.

Legal Proceedings

• The company is involved in ongoing litigation with Bruker (formerly NanoString) regarding patent infringement.
• The company is involved in ongoing litigation with Parse Biosciences regarding patent infringement.
• The company is involved in ongoing litigation with Curio Bioscience regarding patent infringement.
• The company and Vizgen resolved all outstanding litigation between the two companies.

Stakeholder Impact

• Shareholders may be concerned about the continued net losses and the decrease in instrument revenue.
• Employees will be affected by the reduction in force.
• Customers may benefit from the company's focus on improving the cost-effectiveness of its solutions.
• Suppliers may be affected by the company's cost-cutting measures.

Next Steps

• The company plans to continue to evaluate market conditions and may pursue additional sources of funding.
• The company will continue to improve its systems and processes and continue to effectively expand, train and manage its personnel.

Key Dates

Keywords

10x Genomics, revenue, financial results, Q1 2025, litigation settlement, Vizgen, consumables, instruments, gross margin, operating expenses, net loss, reduction in force